Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03672188) tested a drug called VIR-2218 across three parts (A, B, and C). Part A gave participants a single dose of VIR-2218 (at doses ranging from 50 mg to 900 mg) or a placebo. Parts B and C gave participants multiple doses over time (ranging from 20 mg to 200 mg) or a placebo. In total, 86 people started the trial across all groups. The trial was primarily measuring how many participants experienced adverse events (unexpected health changes or symptoms) and whether there were any notable abnormalities in things like blood tests, heart tracings (ECGs), or vital signs. The reported data shows that, among those who received VIR-2218 in the single-dose part (Part A), the number of participants who experienced at least one adverse event ranged from 3 to 5 per dosing group (out of 6–8 people in each group), while 6 out of 12 placebo participants also reported an adverse event. In the multiple-dose parts (B and C), the reported numbers ranged from 0 to 5 participants per group experiencing an adverse event. For clinically significant abnormalities in tests or measurements, the reported data shows that 1 participant per group in Part A (across both VIR-2218 and placebo groups) had a notable finding, while in Parts B and C, no participants were reported to have such abnormalities. Note that results for some groups in Parts B and C were not reported in the submitted data. The reported data also includes measurements of how the drug behaved in the bloodstream (sometimes called pharmacokinetics). For example, the highest level of VIR-2218 detected in the blood (peak concentration) ranged from 155 ng/mL at the lowest single dose to 5,010 ng/mL at the highest single dose, with lower peak levels seen in the multiple-dose groups. The time it took to reach that peak level ranged roughly from about 2.5 to 7.6 hours depending on the group. How long the drug took to clear from the blood (half-life — the time for the amount in the body to halve) ranged from around 2.5 to 5.3 hours across the single-dose groups; this figure was not reported for the multiple-dose groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39389081) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Hepatitis B Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Part A (Single Dose Study):
- You are a man or woman between 18 and 55 years old
- Your body mass index (a measure of body weight relative to height) is between 18 and 32
Parts B and C (Multiple Dose Study):
- You are a man or woman between 18 and 65 years old
- Your body mass index is between 18 and 32
- You have been diagnosed with chronic Hepatitis B virus (HBV) infection for at least 6 months
Who may not be able to join:
Part A (Single Dose Study):
- You have a significant ongoing or recent medical condition that could make participation unsafe (confirm with trial site)
- You have a history of drug or alcohol misuse
- You have previously had a bad reaction to injections given under the skin
Parts B and C (Multiple Dose Study):
- You have a significant ongoing or recent medical condition that could make participation unsafe (confirm with trial site)
- You have significant scarring of the liver or a condition where the liver has become severely hardened
- You have a history of drug or alcohol misuse
- You have previously had a bad reaction to injections given under the skin
- You have a history of liver disease caused by anything other than Hepatitis B
- Your liver has previously stopped working properly (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence of Adverse Events (AEs); Clinical Assessments Including But Not Limited to Laboratory Test Results
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.